sb 216763 has been researched along with Osteosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, JF; Huang, XY; Jing, SF; Li, CD; Wang, DZ; Wei, H | 1 |
| Fukuoka, N; Horie, R; Mori, M; Nakamura, O; Nishimura, H; Yamagami, Y; Yamamoto, T | 1 |
2 other study(ies) available for sb 216763 and Osteosarcoma
| Article | Year |
|---|---|
Antitumor Effect of Docetaxel in Osteosarcoma by the Inhibition of Wnt Signal Channel.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Matrix Metalloproteinase 9; Osteosarcoma; Taxoids; Time Factors; Wnt Signaling Pathway | 2015 |
GSK-3 inhibitor inhibits cell proliferation and induces apoptosis in human osteosarcoma cells.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Humans; Indoles; Maleimides; Osteosarcoma; Up-Regulation | 2016 |